Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study-Reference-Cited by-同舟云学术

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

Published:2016-04-22 Issue:7 Volume:95 Page:1107-1114
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Mondello Patrizia,Steiner Normann,Willenbacher Wolfgang,Wasle Ines,Zaja Francesco,Zambello Renato,Visentin Andrea,Mauro Endri,Ferrero Simone,Ghione Paola,Pitini Vincenzo,Cuzzocrea Salvatore,Mian Michael

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-016-2668-0.pdf

Reference22 articles.

1. Harris NL, Jaffe ES, Diebold J et al (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419–1432

2. Press OW (2013) Selection of first-line therapy for advanced follicular lymphoma. J Clin Oncol 31:1496–1498

3. Czuczman MS, Grillo-López AJ, White CA et al (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276

4. Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423

5. Federico M, Luminari S, Dondi A et al (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506–1513

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma;Transplantation and Cellular Therapy;2024-07

2. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis;Cell Transplantation;2023-01

3. Bendamustine and rituximab is well‐tolerated and efficient in the treatment of indolent non‐Hodgkin ' s lymphoma and mantle cell lymphoma in elderly: A single center observational study;International Journal of Cancer;2022-12-30

4. Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma;Clinical Pharmacology in Drug Development;2022-07-12

5. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group;International Journal of Hematology;2022-05-18